deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT01593254

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)

An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib

Sponsor: Bristol-Myers Squibb

Conditions Chronic Phase Chronic Myeloid Leukemia
Interventions Dasatinib Imatinib
Updated 30 times since 2017 Last updated: May 30, 2023 Started: Sep 12, 2012 Primary completion: Nov 8, 2017 Completion: Apr 12, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01593254, this PHASE2 trial focuses on Chronic Phase Chronic Myeloid Leukemia and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 30 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~May 2019 · 10 months · monthly snapshot~May 2019 – ~Dec 2019 · 7 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Nov 2022 · 31 days · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jun 2025 · 8 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

30 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Oct 2024 — Jun 2025 [monthly]

    Completed PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

▶ Show 25 earlier versions

  1. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE2

  2. Jun 2023 — Jul 2023 [monthly]

    Completed PHASE2

  3. Mar 2023 — Jun 2023 [monthly]

    Completed PHASE2

  4. Feb 2023 — Mar 2023 [monthly]

    Completed PHASE2

  5. Dec 2022 — Feb 2023 [monthly]

    Completed PHASE2

  6. Nov 2022 — Dec 2022 [monthly]

    Completed PHASE2

  7. Oct 2022 — Nov 2022 [monthly]

    Completed PHASE2

  8. Sep 2022 — Oct 2022 [monthly]

    Completed PHASE2

  9. Jun 2022 — Sep 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  10. Jan 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  11. Jan 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2

  12. Dec 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  13. May 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  14. Jul 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  15. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  16. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  17. Feb 2018 — Mar 2018 [monthly]

    Active Not Recruiting PHASE2

  18. Dec 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE2

  19. Oct 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE2

  20. Aug 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE2

  21. Jun 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE2

  22. May 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE2

  23. Mar 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  24. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  25. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Donald E. Morisky
  • ICON Clinical Research
  • MD Anderson Symptom Inventory (MDASI-CML)
  • Molecular MD
  • MultiPharma
  • OBiS, Inc
  • PPD Development, LP
  • Q2 Solutions
  • Steering Committee
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Couruna, Spain , Anaheim, United States , Bangkok, Thailand , Bari, Italy , Beijing, China , Bologna, Italy , Brescia, Italy , Brno, Czechia , Bruges, Belgium , Budapest, Hungary and 82 more locations